Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide once weekly suspension vs sitagliptin in type 2 diabetes (DURATION-NEO-2)
NCT01652729Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2013
- Primary completion
- Apr 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Feb 2013; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01652729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01652729.